Zusammenfassung
Asthma bronchiale bleibt mit einer Prävalenz von 5% für Erwachsene und 10% für Kinder in Deutschland eine häufige Erkrankung. Neuere zellbiologische Daten zeigen eine getrennte Steuerung der Allergie (Interleukin-4- (IL-4-) Pfad) und der eosinophilen Asthma-Entzündung (IL-5-Pfad). Beides muss therapeutisch angegangen werden. Um ein irreversibles bronchiales Remodeling zu verhindern, ist eine frühzeitige Diagnose und konsequente Therapie entscheidend. Ein Asthma bronchiale gilt als gesichert, wenn der anfallsweise Krankheitscharakter nachgewiesen wird und sich eine zumindest intermittierende obstruktive Ventilationsstörung zeigt, die gut auf kurzwirksame β2-Adrenergika anspricht. Die heutige Asthmatherapie ist in vielen Studien gesichert (Evidenzlevel A) und beruht auf einem Stufenplan, der die therapeutischen Maßnahmen nach 4 Schweregraden gliedert. Darunter sind die meisten Patienten weitgehend beschwerdefrei, nächtliche Attacken sind heute eine Seltenheit. Neue Medikamente sollen verbliebene therapeutische Schwachstellen schließen. Antileukotriene und Anti-IgE-Antikörper können zur Reduktion der notwendigen Kortikosteroide beitragen. Pharmaka, die in die IL-4- oder IL-5-Steuerung eingreifen oder das Remodeling verhindern helfen, sind in Entwicklung.
Abstract
Bronchial asthma, with a prevalence in Germany of 5% among adults and 10% among children, remains a frequent disease. Newer cell biological data show a separate regulation of the allergy (interleukin 4, IL-4, pathway) and of the eosinophilic inflammation in asthma (IL-5 pathway). Both conditions require a therapeutic approach. To prevent irreversible bronchial remodeling, early diagnosis and targeted therapy are decisive. Bronchial asthma is regarded as evident when the paroxysmal character of the disease is confirmed and an—at least intermittent—obstructive ventilation disorder is apparent which responds well to short-acting β2-adrenergic agents. Current asthma treatment has been assured in many studies (evidence level A) and is based on therapy in stages which classifies therapeutic measures depending on four grades of severity. Accordingly, most patients are largely without complaints, and nocturnal attacks are now rare. New medications are intended to overcome any remaining therapeutic weak points. Antileukotrienes and anti-IgE antibodies can contribute to reducing the necessary corticosteroids. Pharmaceutical agents that intervene in the IL-4 or IL-5 regulation or prevent remodeling are being developed.
Literatur
Abramson MJ, Puy RM, Weiner JM (2003) Allergen immunotherapy für asthma. Cochrane Database Syst Rev 4: CD001186
Barnes PJ (2003) Pathophysiology of asthma. Eur Respir Mon 23: 84–113
Bel EH, Chanez P (2003) Diagnosis and assessment of asthma. Eur Respir Mon 23: 180–194
Bousquet J, Lockey R, Malling H (1998) WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53: Suppl 54
Bousquet J, Demoly P, Michel FB (2003) Eur Respir Mon 23: 409–428
Castro-Rodriguez JA, Holberg CJ, Morgan WJ et al. (2001) Increased incidence of asthmalike symptoms in girls who become overweight or obese during the school years. Am J Respir Crit Care Med 163: 1334–1349
Chung KF, Stirling RG, Chanez P, Godard P (2003) Severe therapy resistant asthma. Eur Respir Mon 23: 312–338
Cook DG, Strachan DP (1999) Health effects of passive smoking: Summary of effects of parental smoking on the respiratory health of children and implications for research. Thorax 54: 357–366
Corrigan CJ (1995) Elevated IL-4 secretion by T-lymphocytes: a feature of atopy or asthma? Clin Exp Allergy 25: 485–487
Dal Negro RW, Aubier M (2003) Bronchial asthma and gastro-oesophageal reflux. Eur Respir Mon 23: 260–277
Ehnert B, Lau-Schauendorf S, Weber A et al. (1992) Reducing domestic exposure to dust mite allergen reduces bronchial hyperreactivity in sensitive children with asthma. J Allergy Clin Immunol 90: 135–138
Fabbri LM, Romagnoli M, Richeldi L, Olivieri D (2003) Asthma versus chronic obstructive pulmonary disease. Eur Respir Mon 23: 195–210
Fahy JV, Fleming HE, Wong HH (1997) The effect of an anti-IgE monoclonal antibody on the early and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155: 1828–1834
Frew AJ (2003) Allergic basis of asthma. Eur Respir Mon 23: 74–83
Gibson PG, Henry RL, Coughlan JL (2003) Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev 1: CD0011496
Gross NJ (1980) What is this thing called love? – or, defining asthma. Am Rev Respir Dis 121: 203–204
Holgate ST (2004) Lessons learnt from the epidemic of asthma. QJM 97: 247–257
Hollowy JW, Jongepier H, Beghé B et al. (2003) The genetics of asthma. Eur Repir Mon 23: 26–56
Homa DM, Mannino DM, Lara M (2000) Asthma mortality in US Hispanics of Mexican, Puerto Rican and Cuban heritage, 1990–1995. Am J Respir Crit Care Med 161: 504–509
Humbert M, Kay AB (2003) Chronic inflammation in asthma. Eur Repir Mon 23: 126–137
Illi S, von Mutius E, Bergmann R et al. (2001) Upper respiratory tract infections in the first year of life and asthma in children up to the age of 7 years. BMJ 322: 390–395
Johnston SL (2005) Impact of viruses on airway disease. Eur Respir Rev 14: 57–61
Kabesch M, Schaal W, Nicolai T, von Mutius E (1999) Lower prevalence of asthma and atopy in Turkish children living in Germany. Eur Respir J 13: 577–582
Kogevinas M, Anto JM, Sunyer J (1999) Occupational asthma in Europe and other industrialised areas: a population based study. European Community Respiratory Health Survey Study Group. Lancet 22: 1750–1754
Kramer U, Heinrich J, Wjst M, Wichmann HE (1999) Age of entry to day nursery and allergy in later childhood. Lancet 353: 450–454
Kroegel C, Buhl B, Gillissen A, Petro W (2005) Asthma bronchiale versus chronisch-obstruktive Lungenkrankheit (COPD). Dtsch Med Wochenschr 130: 812–818
Lilly CM (2005) Diversity of asthma: Evolving concepts of pathophysiology and lessons from genetics. J Allergy Clin Immunol 115: S526–S531
McFadden ER (2003) Acute severe asthma. Am J Respir Crit Care Med 168: 740–759
Mapp CE, Saetta M, Mastrelli P, Fabbri L (1999) Occupational asthma. Eur Respir Mon 11: 255–285
Mielck A, Reitmeir P, Wjst M (1996) Severity of childhood asthma by socio-economic status. Int J Epidemiol 18: 888–890
Murphy VE, Gibson PG, Smith R, Clifton VL (2005) Asthma during pregnancy: mechanisms and treatment implications. Eur Respir J 25: 731–750
Nationale Versorgungs-Leitlinie Asthma (2005) Fassung September 2005. http://www.asthma.versorgungsleitlinien.de
Osur SL (2005) The management of asthma and rhinitis during pregnancy. J Womens Health 14: 263–276
Panhuysen CI, Bleecker ER, Koeter GH et al. (1998) Characterization of obstructive airway disease in family members of probands with asthma. An algorithm for the diagnosis of asthma. Am J Respir Crit Care Med 157: 1734–1742
Pearce N, Douwes J, Beasley R (2000) Is allergen exposure the major primary cause of asthma? Thorax 55: 424–431
Peebles RS (2004) Viral infections, atopy, and asthma: Is there a causal relationship. J Allergy Clin Immunol 113: S15-S18
Riedler J, Braun-Fahrlander C, Eder W (2001) Early life exposure to farming provides protection against the development of asthma and allergy. Lancet 358: 1129–1133
Ronmark E (1999) Asthma – incidence, remission and risk factors. Umeå University Dissertations, New Series No. 630
Salvi S, Frew A, Holgate ST (1999) Is diesel exhaust a cause for increasing allergies? Clin Exp Allergy 29: 4–8
Sears MR, Greene J, Flannery EM, Herbison GP (2000) Early childhood exposure to pets in the home, sensitation and risk of asthma. Eur Respir J 16 [Suppl]: 555S
Sheffer AL (1995) Global initiative for asthma. NHLBI/WHO workshop report, National Institutes of Health, National Heart, Lung and Blood Institute, Publication No. 95-3659
Siroux V, Pin I, Oryszczyn MP et al. (2000) Relationships of active smoking to asthma and asthma severitiy in the EGEA study. Eur Respir J 15: 470–477
Skobeloff EM, Pivey WH, St. Clair SS, Schoffstall JM (1992) The influence of age and sex on asthma admissions. JAMA 268: 3437–3440
Sunyer J, Spix C, Quenel P (1997) Urban air pollution and emergency admission for asthma in European cities: the APHEA projects. Thorax 52: 760–765
Szczeklik A, Picado C (2003) Aspirin-induced asthma: Advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 111: 913–921
Viegi G, Annesi I, Matteeli G (2003) Epidemiology of asthma. Eur Respir Mon 23: 1–25
von Mutius E, Fritzsch C, Weiland SK et al. (1992) Prevalence of asthma and allergic disorders among children in united Germany. A descriptive comparison. BMJ 305: 1395–1399
von Mutius, Weiland SK, Fritzsch C et al. (1998) Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany. Lancet 351: 862–866
von Mutius E, Sears MR (2003) Risk factors for development of asthma. Eur Respir Mon 23: 57–73
Wilkonson J, Grimley S, Collins A et al. (1998) Linkage of asthma to markers on chromosome 12 in a sample of 240 families using quantitative phenotypes scores. Genomics 53: 251–259
World Health Organization (2000) Bronchial asthma. WHO fact sheet No. 206. http://www.who.int/inf-fs/en/fact206.html
Interessenkonflikt
Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schmidt, M. Asthma bronchiale. Internist 47, 835–852 (2006). https://doi.org/10.1007/s00108-006-1671-2
Issue Date:
DOI: https://doi.org/10.1007/s00108-006-1671-2